Business
uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, July 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing
About this update from Uniqure N.v.
[{"type":"text","content":"LEXINGTON, Mass. and AMSTERDAM, The Netherlands, July 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that eight data presentations, of which three are oral presentations, will be delivered at the International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress being held July 17-21, 2021. Specific details on uniQure’s presentations at ISTH include: Title: Five Year Data Confirms Stable FIX Expression and Sustained Reductions in Bleeding and Factor IX Use Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B (Abstract OC 26.3)Oral Session Title: Hemostatic Agents and Hemostatic EfficacyDate and Time: Monday, July 19, 11:00 – 12:00 p.m. EDT Title: Clinical Outcomes in Adults with Hemophilia B With and Without Pre-existing Neutralizing Antibodies to AAV5: 6 Month Data from the Phase 3 Etranacogene Dezaparvovec HOPE-B Gene Therapy Trial (Abstract OC 67.3)Oral Session Title: Safety and Efficacy in Gene Therapy for HemophiliaDate and Time: Wednesday, July 21, 10:00 – 11:00 a.m. EDT Title: Liver Safety Case Report from the Phase 3 HOPE-B Gene Therapy Trial in Adults with Hemophilia B (Abstract OC 67.4)Oral Session Title: Safety and Efficacy in Gene Therapy for HemophiliaDate and Time: Wednesday, July 21, 10:00 – 11:00 a.m. EDT Title: Etranacogene dezaparvovec (AAV5-Padua hFIX variant, AMT-061), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: 2.5 Year data from a Phase 2b Trial (Live Poster, Abstract LPB0020)Poster Session Title: Oligonucleotide TherapeuticsLive ePoster Date and Time: Sunday, July 18, 3:00 – 4:00 p.m. EDT Title: 52 Week Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Severe or Moderate-Severe Hemophilia B: Data from the Phase 3 HOPE-B Gene Therapy Trial (Abstract PB0653)Date and Time: All ePosters will be made available on Saturday, July 17Title: Management of Infusion Reactions: Lessons from the Phase 3 HOPE-B Gene Therapy Trial of Etranacogene Dezaparvovec in Adults with Hemophilia B (Abstract PB0659)Date and Time: All ePosters will be made available on Saturday, July 17 Title: Real-world Outcomes in People with Severe Hemophilia B Receiving FIX Prophylaxis across Europe: A CHESS II Anal...